{"name": "Inspire Pharmaceuticals",
 "permalink": "inspire-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/inspire-pharmaceuticals",
 "homepage_url": "http://www.inspirepharm.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@inspirepharm.com",
 "phone_number": "919-941-9777",
 "description": "",
 "created_at": "Tue Sep 07 03:09:32 UTC 2010",
 "updated_at": "Tue Sep 07 03:09:58 UTC 2010",
 "overview": "\u003Cp\u003EInspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development. The Company\u00e2\u20ac\u2122s portfolio of products includes AzaSite, Elestat, Restasis, Denufosol tetrasodium, Prolacria, AzaSite and INS115644, INS117548. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       40],
      "assets/images/resized/0010/0803/100803v1-max-150x150.png"],
     [[220,
       59],
      "assets/images/resized/0010/0803/100803v1-max-250x250.png"],
     [[220,
       59],
      "assets/images/resized/0010/0803/100803v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Adrian",
      "last_name": "Adams",
      "permalink": "adrian-adams",
      "image": null}},
   {"is_past": false,
    "title": "Senior Vice President and CTO",
    "person":
     {"first_name": "Robert",
      "last_name": "M. Savel, II",
      "permalink": "robert-m-savel-ii",
      "image": null}},
   {"is_past": false,
    "title": "Executive Vice President and Chief, Research \u0026 Development",
    "person":
     {"first_name": "Benjamin",
      "last_name": "Yerxa",
      "permalink": "benjamin-yerxa",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 430000000.0,
   "price_currency_code": "USD",
   "term_code": "cash",
   "source_url": "http://www.merck.com/newsroom/news-release-archive/corporate/2011_0405.html?WT.svl=content\u0026WT.pi=content+Views",
   "source_description": "Merck to Acquire Inspire Pharmaceuticals, Inc.",
   "acquired_year": 2011,
   "acquired_month": 4,
   "acquired_day": 5,
   "acquiring_company":
    {"name": "Merck \u0026 Co.",
     "permalink": "merck-co-inc",
     "image":
      {"available_sizes":
        [[[123,
           38],
          "assets/images/resized/0004/7814/47814v3-max-150x150.jpg"],
         [[123,
           38],
          "assets/images/resized/0004/7814/47814v3-max-250x250.jpg"],
         [[123,
           38],
          "assets/images/resized/0004/7814/47814v3-max-450x450.jpg"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "4222 Emperor Boulevard",
    "address2": "Suite 200",
    "zip_code": "27703",
    "city": "Durham",
    "state_code": "NC",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ISPH"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}